Reply to: "Correspondence on the <BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update>"

J Hepatol. 2022 May;76(5):1240-1241. doi: 10.1016/j.jhep.2022.02.026. Epub 2022 Mar 11.

Authors

Maria Reig¹, Jordi Bruix²

Affiliations

¹ BCLC group, Liver Unit, Digestive Disease Institute, Hospital Clínic, IDIBAPS CIBEREHD, University of Barcelona, Barcelona, Spain. Electronic address: mreig1@clinic.cat.
² BCLC group, Liver Unit, Digestive Disease Institute, Hospital Clínic, IDIBAPS CIBEREHD, University of Barcelona, Barcelona, Spain. Electronic address: jbruix@clinic.cat.

PMID: 35283212
DOI: 10.1016/j.jhep.2022.02.026

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Hepatocellular* / pathology
Humans
Liver Neoplasms* / pathology
Neoplasm Staging
Prognosis
Retrospective Studies